Many studies have shown that lactoferrin and transferrin have antimicrobial activity against gram-negative bacteria, but a mechanism of action has not been defined. We hypothesized that the iron-binding proteins could affect the gram-negative outer membrane in a manner similar to that of the chelator EDTA. The ability of lactoferrin and transferrin to release radiolabeled lipopolysaccharide (LPS) from a UDP-galactose epimerasedeficient Escherichia coli mutant and from wild-type Salmonella typhimurium strains was tested. Initial studies in barbital-acetate buffer showed that EDTA and lactoferrin cause significant release of LPS from all three strains. Further studies found that LPS release was blocked by iron saturation of lactoferrin, occurred between pH 6 and 7.5, was comparable for bacterial concentrations from 104 to 107 CFU/mI, and increased with increasing lactoferrin concentrations. Studies using Hanks balanced salt solution lacking calcium and magnesium showed that transferrin also could cause LPS release. Additionally, both lactoferrin and transferrin increased the antibacterial effect of a subinhibitory concentration of rifampin, a drug excluded by the bacterial outer membrane. This work demonstrates that these iron-binding proteins damage the gram-negative outer membrane and alter bacterial outer membrane permeability.
The host defense systems active at mucosal surfaces are poorly characterized, even though most bacterial infections develop through extension of disease from these sites. Mucosal secretions have an antibacterial armamentarium very different from that of serum (28, 41) . While there is less complement and relatively little immunoglobulin G (IgG) and IgM, there are high concentrations of secretory IgA (sIgA), lysozyme, and the iron-binding protein lactoferrin. Lactoferrin is found at low levels in serum but has been measured at concentrations of up to 9 to 14 mg/ml in mucosal secretions (28, 29, 41, 50, 51) . Of further interest, this protein is also present at high concentrations within the specific granules of polymorphonuclear leukocytes (30, 41, 51) .
Both in vivo and in vitro studies indicate that lactoferrin has antibacterial activity (12) . A large number of independent investigators have found that lactoferrin has a bacteriostatic effect on a diverse spectrum of gram-negative bacteria and that this effect is blocked if the protein is saturated with iron (7, 15, 21, 35, 41, 42, 46, 48) . The major hypothesis advanced for this activity has been that lactoferrin produces an iron-deficient environment that limits bacterial growth.
Several lines of evidence have suggested that lactoferrin may have effects on gram-negative bacteria in addition to those resulting from nutritional deprivation of iron. First, several investigators have found that the antimicrobial activity of lactoferrin against bacteria is enhanced with concurrent exposure of the organisms to IgG or sIgA (9, 39, (45) (46) (47) . It has been suggested that this interaction develops because antibodies directed against bacterial siderophores suppress bacterial iron metabolism more than does lactoferrin alone. However, this hypothesis has not yet been confirmed, and a precise explanation for the combined effect has not been offered (17) .
Second, although it is controversial, work by Arnold and associates has suggested that lactoferrin has direct bactericidal activity against several bacteria, including strains of Escherichia coli, Vibrio cholerae, Streptococcus mutans, Streptococcus pnelimoniae, and Legionella pneumophila (2- 5, 10) . As in the bacteriostasis produced by lactoferrin, this effect is inhibited by iron saturation of the protein. The effect has not been reproduced by exposure of bacteria to an iron-poor environment alone (5) . Also, the activity against L. pneumophila is inhibited by the addition of magnesium (10) . Immunofluorescence studies have demonstrated that lactoferrin appears to be cell associated (3); on this basis, these investigators have postulated that membrane destabilization may contribute to the bactericidal effect of lactoferrin (10) .
As for lactoferrin, several studies have indicated that the serum iron-binding protein transferrin also has antibacterial activity (12, 14) . The antibody-and complement-dependent bactericidal activity of serum against E. coli, Neisseria gonorrhoeae, and Pasteurella septica can be blocked by saturation of the serum iron-binding capacity (13, 20, 36) . As these assays are performed in the presence of fresh serum that contains partially saturated transferrin, it suggests that this protein contributes to the serum-mediated killing of gram-negative bacteria. Moreover, similar to some of the inconsistencies observed with lactoferrin, a mechanism by which iron deprivation could alter the efficiency of complement-mediated antibacterial activity has not been defined.
In a different field, researchers studying the structure of gram-negative bacteria have shown that synthetic metal chelators have significant antibacterial activity against enteric gram-negative bacilli (26, 34) . EDTA releases up to 50% of the lipopolysaccharide (LPS) from the bacterial outer membrane, increases the permeability of the membrane to hydrophobic molecules, and sensitizes the bacteria to the effects of complement and lysozyme (34) . These and other studies have contributed to a model of the gram-negative outer membrane as an asymmetric lipid bilayer with large LPS molecules restricted to the outer leaflet and nonpolar phospholipids on the inner membrane. While hydrophobic LPS-LPS or LPS-protein interactions contribute to maintenance of outer leaflet integrity, the presence of divalent cations within the membrane appears to be critical to stabilizing the strong negative charges of the core oligosaccharide chain of the LPS molecules (16) . By binding these membrane-associated cations, EDTA releases LPS molecules from the outer leaflet. Moreover, if the released LPS is replaced by nonpolar phospholipids from the inner leaflet, the membrane becomes more permeable to hydrophobic agents (such as rifampin) that are normally excluded by the hydrophilic LPS barrier (26, 34) .
The transferrin proteins from different species have been shown to bind a wide spectrum of metal ions in addition to iron, including copper, chromium, cobalt, cadmium, manganese, nickel, indium, gallium, aluminum, scandium, and zinc (14) . Although the spectrum of metal binding has not been fully characterized for human lactoferrin and transferrin, we hypothesized that these proteins could be broadly active as chelators and could have an effect on the gram-negative outer membrane similar to that of EDTA. We report that, in a manner comparable to that of this synthetic cheiator, lactoferrin causes LPS release from enteric gram-negative bacteria and that both iron-binding proteins alter the permeability of the gram-negative outer membrane.
MATERIALS AND METHODS Lactoferrin, transferrin, and antiserum preparations. Human lactoferrin purified from milk was purchased commercially (Sigma Chemical Co., St. Louis, Mo., or CalbiochemBehring, La Jolla, Calif.), as was human transferrin purified from serum (Sigma). The following antiserum preparations were purchased commercially and used to test the purity of lactoferrin: rabbit anti-human lactoferrin (Organon Teknika, Malvern, Pa.), goat anti-human transferrin (Organon Teknika), goat anti-human lysozyme (Kallestad Laboratories, Inc., Austin, Tex.), and goat anti-human stgA ( (38) . Briefly, the pelleted cells were suspended in 200 ,ul of solubilizing buffer, and the supernatants were lyophilized and resuspended in 100 pl of solubilizing buffer. All samples were treated with proteinase K for 1 h at 60°C, boiled for 10 min, and redigested with proteinase K. Discontinuous SDS-PAGE using the Laemmli system was performed with 4.5% stacking and 15% resolving gels prepared with either bisacrylamide or AcrylAide (FMC BioProducts, Rockland, Maine) cross-linkers. The gels were subsequently silver stained, dried, and autoradiographed (22) .
Effect of lactoferrin and transferrin on bacterial susceptibility to rifampin. E. coli CL99-2 was grown to a density of 108 CFU/ml in modified WMS with 0.03 mM galactose, and a bacterial inoculum containing 5 x i05 CFU was added to 1 ml of WMS broth with or without EDTA, lactoferrin, or rifampin. The mixture was incubated at 37°C; portions were removed at 0, 2, and 4 h, and bacterial colony counts were determined by plating on tryptic soy agar (Sigma).
Statistical analysis. Data were analyzed by independent and paired Student's t tests by using the ABSTAT software package (Anderson-Bell, Canon City, Colo).
RESULTS
The initial studies were performed with lactoferrin from Sigma. The purity of the lactoferrin was ascertained by SDS-PAGE with a modified silver stain showing a single band of approximately 80,000 Da (Fig. 1A) . This was further confirmed by double-immunodiffusion experiments with commercial anti-human lactoferrin, anti-human transferrin, and anti-human sIgA showing a precipitin band only with anti-human lactoferrin (data not showvn). Finally, immunoblotting with commercial antisera showed that anti-human lactoferrin identified a major 80,000-Da band and a weak second band of approximately 65,000 Da; anti-human transferrin, anti-human sIgA, and anti-human lysozyme were not reactive (Fig. 1B) .
The commercial lactoferrin preparations and apolactoferrin solutions were found to be 3 to 10% saturated, apotransferrin solutions were found to be 0.2% saturated, and saturated lactoferrin solutions were found to be 101 to 102% saturated. Initial studies performed with 104 CFU/ml at pH 6.8 with lactoferrin, transferrin, and EDTA found that untreated and apolactoferrin-treated preparations produced significant'LPS release, although less than that produced by EDTA (Table 1 (Fig. 2) . At pH 7.0, both lactoferrin and EDTA caused comparable LPS release for bacterial concentrations from 104 to 107 CFU/ml, with the fraction of LPS released differing but being fixed for each (Fig. 3) . Increasing lactoferrin concentrations caused increased 3H release over the range of 0.05 to 2 mg/ml, approaching a limit of 16 to 18% 3H release (Fig. 4) . The release of LPS over time was evaluated, and both lactoferrin and EDTA were found to cause significant release within 5 min; continued release occurred through 30 min (Fig. 5) .
As these studies were performed with a UDP-galactose epimerase-deficient mutant E. coli isolate, additional LPS release studies were performed with two smooth, wild-type S. typhimurium strains, SL696 and SH4247, that also incorporate a large percentage of exogenous galactose into LPS (23). Lactoferrin and EDTA, but not transferrin, released LPS from both strains, although the amount of LPS released differed for the two isolates (Fig. 6) .
In additional studies, we investigated the effects of different buffer systems on the membrane effects of lactoferrin and transferrin (Table 2) . The results in a Tris buffer were comparable to those in barbital-acetate. However, in studies with Tris, the buffer was found to release large quantities of LPS by itself and limited the reproducibility of the assay. In complete HBSS, LPS release was not observed with EDTA or with either of the iron-binding proteins. In contrast, lactoferrin and EDTA induced LPS release both in HBSS lacking calcium and magnesium and in HBSS lacking calcium, magnesium, and bicarbonate; significantly greater release was observed in the HBSS containing bicarbonate. In these studies, limited LPS release from the E. coli strain was also observed with transferrin exposure in HBSS lacking calcium and magnesium, although the release was less than that observed with lactoferrin.
Studies of LPS release in HBSS lacking calcium and magnesium were repeated by using lactoferrin obtained from a second vendor (Calbiochem). This second lactoferrin preparation also caused LPS release from all three bacterial species (Table 3) . Prior work on EDTA-mediated LPS release showed both that the chelator releases a fixed fraction of LPS and that the retained and released LPS fractions are equally heterogeneous in O-polysaccharide chain length (23, 26) . Assuming that the mechanism of lactoferrin is comparable to that of EDTA, it should also release a heterogeneous population of LPS molecules. This hypothesis was confirmed by analyzing the composition of LPS released from E. coli CL99-2 and S. typhimurium SL696 by using SDS-PAGE. With both strains, lactoferrin and EDTA caused identical release of heterogeneous LPS populations (Fig. 7) .
To determine whether the lactoferrin-mediated LPS release is associated with a change in outer membrane permeability, we tested the effect of EDTA, lactoferrin, and transferrin on the susceptibility of E. coli CL99-2 to the antibiotic rifampin, which is normally excluded by the outer membrane. EDTA, lactoferrin, and transferrin were all bacteriostatic by themselves, and each had a more than additive effect in increasing bacterial killing due to a subinhibitory concentration of rifampin. The activity of lactoferrin was almost completely eliminated by iron saturation of the protein (Table 4) . typhimurium SL696 and SH4247 by lactoferrin (2 mg/ml) (LF), transferrin (2 mg/ml) (TF), and 2 x 10-5 M EDTA in barbital-acetate buffer (pH 7.0) (nmean ± SEM of 10 experiments). *, P < 0.0005 versus buffer; **, P < 0.05 versus buffer.
DISCUSSION
Gram-negative bacilli have an outer membrane composed of an asymmetric lipid bilayer, with the large LPS molecules restricted to the outer leaflet (26, 34) . The LPS molecules are anionic and appear to be stabilized within the membrane by associated cations, including calcium, magnesium, and iron (16) . By binding the membrane-stabilizing cations, EDTA releases LPS in the outer membrane (26) . Concurrent with the LPS release, the outer memnbrane becomes more permeable to agents, such as riampin, that are normally excluded Lactoferrin and EDTA caused LPS release in three different buffer systems with low calcium and magnesium concentrations, but their activity was blocked by the high concentrations of calcium and magnesium found in HBSS (0.00125 M and 0.001 M, respectively). The activity of lactoferrin was enhanced when bicarbonate was present, suggesting that it could act as a companion anion for the chelation of metal ions. This is consistent with the known chelating properties of the metal-binding proteins (57) . That exogenous calcium and magnesium ions block the activity of lactoferrin and transferrin suggests that the ability of the proteins to chelate these ions may be important for the observed effects. However, recent work has suggested that lactoferrin may form tetramers in the presence of high concentrations of calcium (6). This could limit the biological activity of the protein and would be an alternative explanation for calcium blocking the effect of this protein. That the concentrations of calcium and magnesium in complete HBSS block LPS release by lactoferrin clearly may limit the physiologic relevance of the observations. To determine the importance of these studies it will be necessary to further define the influence of these two cations on the ability of lactoferrin to release LPS.
Although transferrin altered susceptibility to rifampin, it did not release LPS in all buffer systems, nor did it release as large a percentage of LPS as did lactoferrin. This suggests either that differences in chelating ability are important for the LPS release or that an additional mechanism contributes to the effect of lactoferrin. Although we are unaware of relative studies on the ability of the two proteins to chelate calcium and magnesium, the two proteins do differ in their ability to chelate iron; lactoferrin is the stronger chelator (1, 53). Furthermore, transferrin is anionic at physiologic pH (pl -5.5), while lactoferrin is very cationic (pl -8.5) (32, 60) . Because it is cationic, lactoferrin may share a second mechanism of action with a family of polycationic agents. These compounds include polylysine, protamine, the antimicrobial agents polymyxin B and polymyxin B nonapeptide (PMBN), and several cationic proteins isolated from neutrophils (55, 56, 58) .
In a manner similar to that of EDTA, the polycationic compounds increase the permeability of the outer membrane to hydrophobic agents, although the compounds have heterogeneous effects and their mechanisms of action are not fully understood. Polymyxin B and PMBN cause both permeability change and LPS release, while a neutrophil bactericidal effect/permeability-increasing protein enhances membrane permeability but does not release LPS. The activity of these polycationic compounds may be the result of an ability to insert into the bacterial outer membrane by binding to the anionic LPS molecules. Differences in binding or membrane insertion could then explain the observed variability in effects (56) . As several studies have suggested that lactoferrin can be associated with the bacterial cell membrane, it is reasonable to postulate that lactoferrin may also share a mechanism of action with the polycationic compounds (3, 40) .
The demonstration of a more-than-additive interaction between the iron-binding proteins and rifampin is consistent with the proteins altering outer membrane permeability, although other explanations for the effect have not been excluded. Also, the variability between lactoferrin and transfemn in relation to the effects on LPS release and membrane permeability is not unlike the variability noted in the polycationic compounds (56) . More-detailed studies will be necessary to clarify the precise mechanisms of outer membrane damage.
If these effects are demonstrable at calcium and magnesium concentrations that exist in vivo, the ability of lactoferrin and transferrin to alter the structure of the outer membranes of gram-negative bacteria may supplement their ability to deprive bacteria of iron. This could contribute to their bacteriostatic (and, in the case of lactofemn, possibly bactericidal) activities. Perhaps more importantly, the membrane effects of the iron-binding proteins may allow them to amplify other antimicrobial systems. Prior work with EDTA and the polycationic agent PMBN has shown that the compounds can enhance the bactericidal effects of antibiotic agents, the complement system, and lysozyme (11, 26, 34, 43, 44, 50) . In 1974, Leive suggested that, except for its toxicity, EDTA might have a valuable role as an antibiotic adjuvant (26) . The present work suggests that lactoferrin and transferrin may have comparable effects. A lactoferrinmediated alteration in outer membrane structure could explain the observed additive effects of lactofemn and sIgA (9, 39, (45) (46) (47) . Moreover, there is limited evidence suggesting that lysozyme and lactoferrin may have synergistic activity (9) . Such an interaction would be relevant physiologically as the proteins are found at their highest concentrations at the same sites in vivo. Together they may function as a potent bactericidal system against the gram-negative bacteria that are only minimally affected by either protein alone.
